Full Breakdown
Novo Nordisk's U.S. Public Affairs Head Departs Amid Restructuring
1/5/2026, 9:36:47 PM
Departure of Key Executive
Jennifer Duck, the head of public affairs for Novo Nordisk in the United States, has left the company as part of a broader restructuring effort. This decision comes at a critical time for the Danish obesity drugmaker, which is striving to regain market share against its U.S. rival, Eli Lilly, in the competitive weight-loss sector. The internal memo announcing her departure indicated that Duck had chosen to pursue other opportunities outside the organization after more than six years in her role. Chris Pernie, an executive director of government affairs at Novo, will temporarily lead the U.S. public affairs team.
Context of the Restructuring
Novo Nordisk is currently navigating significant challenges, including pressure from U.S. President Donald Trump regarding drug pricing and access to its obesity and diabetes medications. The company has faced scrutiny over its pricing strategies and has recently launched a new pill form of its drug Wegovy. CEO Mike Doustdar is implementing a major global restructuring that includes the elimination of approximately 9,000 jobs across various departments and regions, aiming to restore investor confidence after a year marked by multiple profit warnings and a nearly 50% decline in share value.
Official Statements & Responses
Novo Nordisk confirmed Duck's departure, stating that her last day was the previous Friday. The company emphasized the need for a renewed focus on its public affairs strategy as it seeks to address the competitive pressures in the U.S. market. Duck's tenure included involvement in significant initiatives related to the U.S. Senate's HELP Committee and the Inflation Reduction Act's pricing processes.
Criticism & Opposition
While the restructuring aims to streamline operations, it has drawn criticism regarding the potential impact on the company's ability to effectively advocate for its interests in a challenging regulatory environment. Analysts have raised concerns that the departure of a key figure like Duck could hinder Novo's efforts to navigate the complexities of U.S. healthcare policy and public perception.
What's Next
As Novo Nordisk continues to adapt to the evolving landscape of the pharmaceutical industry, the company is expected to focus on enhancing its public affairs strategy and addressing the competitive challenges posed by Eli Lilly and other market players. The interim leadership under Chris Pernie will be crucial in guiding the U.S. public affairs team through this transitional period.
Verbatim Quotes
“has made the personal decision to leave Novo Nordisk and pursue other opportunities outside of the organization” — Internal Memo
“CEO Doustdar is trying to restore investor confidence by sharpening Novo's focus, after a tough year in which the company issued multiple profit warnings and saw its shares almost halve in value.” — Industry Analyst
